Country reports
Our Country Reports, published in Pharmaceutical Market Europe, explore the business and healthcare environment in a specific country, in Europe or beyond, developing or developed. The reports take an in-depth look at the impact of disease burden on healthcare budgets and treatment provision; how healthcare is financed; the population’s willingness to self-treat; the biggest pharma companies in the region; alongside the appetite, capacity and appropriateness of manufacturing infrastructure and the impact of the regulatory environment and much more...
Country report: Italy
Italy emerged from economic recession in 2010 with gross domestic product (GDP) growing one per cent on rising exports; economic growth will, however, be slow and modest until 2015
20 Jun 2011
Country report: Turkey
Turkey has always been a bridge between Europe and Asia with untapped potential in a variety of industries. With a population of about 75 million and GDP growth of 7.8 per cent based on IMF's 2010 forecast, it represents a unique opportunity for the pharmaceutical industry.
25 May 2011
Country report: Sweden
Although the Swedish economy is predominantly based on the exports of raw materials and industrial products, the country also has a strong heritage of pharmaceutical R&D and manufacturing and exported pharmaceutical products at a value of SEK68bn in 2009 (7 per cent of total exports).
12 Apr 2011
Country report: China
China's healthcare reforms include incremental investment of RMB850bn by 2011, to support universal healthcare coverage for China's population of 1.3 billion, with further plans for primary healthcare insurance schemes and construction of urban and rural primary healthcare medical facilities
25 Mar 2011
Focus on Germany
While Germany has long been one of Europe’s most attractive pharmaceutical markets thanks to free pricing, this is set to change soon under new regulation with particular focus on price negotiations for patent-protected drugs
21 Feb 2011
Focus on Slovakia
The Slovak healthcare system has undergone significant reform in recent years, and the new Government’s policies look set to continue this change
04 Nov 2010
Focus on Spain
Overstretched primary care services, drug price pressure resulting from the global financial crisis and regionally managed healthcare budgets together create a challenging environment for the pharmaceutical industry
15 Sep 2010
Focus on UK
07 Jul 2010
Focus on the Netherlands
In a healthcare system where insurers wield increasing power, huge pressure is being exerted to cut prices of both branded and generic drugs
09 Mar 2010
Previous 1 Next